公开(公告)号：US20240285704A1

公开(公告)日：2024-08-29

申请号：US18406671

申请日：2024-01-08

Applicant: FP Nutraceuticals, LLC

Inventor： Timothy M. Marshall

IPC: A61K36/185 ,  A23L33/105 ,  A23L33/115 ,  A23L33/125 ,  A23L33/155 ,  A23L33/16 ,  A23L33/165 ,  A23L33/175 ,  A61K9/00 ,  A61K31/015 ,  A61K31/05 ,  A61K31/07 ,  A61K31/122 ,  A61K31/145 ,  A61K31/16 ,  A61K31/192 ,  A61K31/194 ,  A61K31/198 ,  A61K31/232 ,  A61K31/28 ,  A61K31/30 ,  A61K31/315 ,  A61K31/355 ,  A61K31/375 ,  A61K31/385 ,  A61K31/4188 ,  A61K31/455 ,  A61K31/51 ,  A61K31/525 ,  A61K31/592 ,  A61K31/593 ,  A61K31/675 ,  A61K31/69 ,  A61K31/714 ,  A61K33/06 ,  A61K33/18 ,  A61K36/03 ,  A61K36/42 ,  A61K36/45

CPC classification number: A61K36/185 ,  A23L33/105 ,  A23L33/115 ,  A23L33/125 ,  A23L33/155 ,  A23L33/16 ,  A23L33/165 ,  A23L33/175 ,  A61K9/0056 ,  A61K31/015 ,  A61K31/05 ,  A61K31/07 ,  A61K31/122 ,  A61K31/145 ,  A61K31/16 ,  A61K31/192 ,  A61K31/194 ,  A61K31/198 ,  A61K31/232 ,  A61K31/28 ,  A61K31/30 ,  A61K31/315 ,  A61K31/355 ,  A61K31/375 ,  A61K31/385 ,  A61K31/4188 ,  A61K31/455 ,  A61K31/51 ,  A61K31/525 ,  A61K31/592 ,  A61K31/593 ,  A61K31/675 ,  A61K31/69 ,  A61K31/714 ,  A61K33/06 ,  A61K33/18 ,  A61K36/03 ,  A61K36/42 ,  A61K36/45 ,  A23V2002/00

Abstract: The compositions of this disclosure provide broad-spectrum nutrient supplementation to support the health of multiple organ and tissue systems in which mitochondrial function plays a fundamental role. In particular, the formulations promote neuroprotective, cardioprotective, immunosupportive, and anti-aging benefits. Also provided herein are novel, neuroprotective preparations containing a combination of broad- or full-spectrum hemp oil extract combined with niacinamide, a non-flushing form of vitamin B3, and methods of use are described allowing for safe, effective, and convenient use of a neuroprotective, antioxidant preparation for general and clinical use.

公开(公告)号：US20240285568A1

公开(公告)日：2024-08-29

申请号：US18641536

申请日：2024-04-22

Applicant: William H. Cross, III

Inventor： William H. Cross, III

IPC: A61K31/198 ,  A61K31/145 ,  A61K31/205 ,  A61K31/4045 ,  A61K31/714 ,  A61P25/02

CPC classification number: A61K31/198 ,  A61K31/145 ,  A61K31/205 ,  A61K31/4045 ,  A61K31/714 ,  A61P25/02

Abstract: The invention provides compositions and methods to treat diabetic neuropathies. In particular, the invention provides combinations of at least two types of antioxidants have complementary effects for use against diabetic neuropathies. The two types of antioxidants include: antioxidants that comprise stabilizing heteroatoms and antioxidants with extended conjugated segments in a ring structure. At least one of each type of provided antioxidant has a pro-oxidative or conditionally pro-oxidative effect.

公开(公告)号：US12070468B2

公开(公告)日：2024-08-27

申请号：US17984734

申请日：2022-11-10

Applicant: The Trustees of Columbia University in the City of New York

Inventor： Carrie J. Shawber ,  June K. Wu ,  Ajit Muley

IPC: A61K31/145 ,  A61K31/407 ,  A61K31/501 ,  A61K31/69 ,  A61K38/06 ,  A61K38/07 ,  A61P9/14

CPC classification number: A61K31/69 ,  A61K31/145 ,  A61K31/407 ,  A61K31/501 ,  A61K38/06 ,  A61K38/07 ,  A61P9/14

Abstract: Provided herein are methods and compositions for treating and preventing vascular malformations including lymphatic, venous, capillary, arteriovenous, and combinations thereof. Methods of treatment and prevention include the administration of proteasome inhibitors, omipalisib, disulfiram, and agents which target genes in the PI3K/AKT/mTOR or RAS/RAF/MAPK pathways, including but not limited to Pik3ca, Pik3r3, Tsc2, Rasa1, Map2k2, and Glmn.

公开(公告)号：US20240277730A1

公开(公告)日：2024-08-22

申请号：US18548657

申请日：2022-03-03

Applicant: Board of Regents of the University of Nebraska ,  THE CURATORS OF THE UNIVERSITY OF MISSOURI

Inventor： Kamlendra Singh ,  Siddappa Byrareddy ,  Arpan Acharya

IPC: A61K31/553 ,  A61K31/145 ,  A61K31/277 ,  A61K31/395 ,  A61K31/404 ,  A61K31/4174 ,  A61K31/428 ,  A61K31/4439 ,  A61K31/4709 ,  A61K45/06

CPC classification number: A61K31/553 ,  A61K31/145 ,  A61K31/277 ,  A61K31/404 ,  A61K31/4174 ,  A61K31/428 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/5545 ,  A61K45/06

Abstract: The present invention relates to compounds, compositions, and methods, for treating viral infections. In particular, entry inhibitor compounds are disclosed for treatment of coronavirus infections, including SARS-COV-1 and SARS-COV-2 infections. The compounds bind to the interface of a SARS-COV-2 spike protein receptor binding domain (RBD) and a host cell ACE-2 receptor. The entry inhibitor compounds show antiviral activity, favorable kinetics, and temporally act at the entry of SARS-COV-2 infection. In embodiments, the compounds are used as medicaments for the inhibition of viral replication including SARS-COV-1 and/or SARS-COV-2 replication, for the treatment or prophylaxis of viral infections including SARS-COV-1 and SARS-COV-2 infections, and/or for the treatment or prophylaxis of an illness due to SARS-COV-1 and SARS-COV-2 infections.

公开(公告)号：US20240261249A1

公开(公告)日：2024-08-08

申请号：US18435962

申请日：2024-02-07

Applicant: PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION ,  KOSIN UNIVERSITY INDUSTRY-ACADEMY COOPERATION

Inventor： Hwayoung YUN ,  Jee-Yeong JEONG ,  Jinsook KWAK ,  Min Jung KIM ,  Soyeong KIM

IPC: A61K31/277 ,  A61K31/145 ,  A61P35/00 ,  C07C255/58 ,  C07C317/22

CPC classification number: A61K31/277 ,  A61K31/145 ,  A61P35/00 ,  C07C255/58 ,  C07C317/22 ,  C07C2601/04 ,  C07C2601/14

Abstract: The present invention relates to a novel squaramide derivative and a use thereof and provides a novel derivative through the strategy of replacing a compound having a urea core with the bioisolate squaramide, whereby the derivative exhibits an anticancer activity through eIF2α phosphorylation efficacy, wherein squaramide has a characteristic structure retaining a double bond linked to the carbonyl groups and the squaramide structure can be prepared by mediating a precursor bearing an amine group to the squarate ring, which is a squaric ring, through a conjugate addition reaction.

公开(公告)号：US11998577B2

公开(公告)日：2024-06-04

申请号：US17682051

申请日：2022-02-28

Applicant: ABBOTT LABORATORIES

Inventor： Alejandro Barranco Perez ,  Maria Ramirez Gonzalez ,  Rachael Buck ,  Enrique Vazquez Hernandez

IPC: A61K35/747 ,  A23L33/00 ,  A23L33/125 ,  A23L33/135 ,  A23L33/15 ,  A61K9/107 ,  A61K31/015 ,  A61K31/047 ,  A61K31/07 ,  A61K31/122 ,  A61K31/14 ,  A61K31/145 ,  A61K31/205 ,  A61K31/355 ,  A61K31/405 ,  A61K31/4188 ,  A61K31/4415 ,  A61K31/519 ,  A61K31/525 ,  A61K31/593 ,  A61K31/702 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  A61K31/714 ,  A61K33/06 ,  A61K33/26 ,  A61K33/30 ,  A61K35/20 ,  A61K35/745 ,  A61K47/02 ,  A61K47/12 ,  A61K47/14 ,  A61K47/22 ,  A61K47/24 ,  A61K47/26 ,  A61K47/36 ,  A61K47/42 ,  A61K47/44 ,  A61K47/46 ,  A61P1/14

CPC classification number: A61K35/747 ,  A23L33/125 ,  A23L33/135 ,  A23L33/15 ,  A23L33/40 ,  A61K9/107 ,  A61K31/015 ,  A61K31/047 ,  A61K31/07 ,  A61K31/122 ,  A61K31/14 ,  A61K31/145 ,  A61K31/205 ,  A61K31/355 ,  A61K31/405 ,  A61K31/4188 ,  A61K31/4415 ,  A61K31/519 ,  A61K31/525 ,  A61K31/593 ,  A61K31/702 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  A61K31/714 ,  A61K33/06 ,  A61K33/26 ,  A61K33/30 ,  A61K35/20 ,  A61K35/745 ,  A61K47/02 ,  A61K47/12 ,  A61K47/14 ,  A61K47/22 ,  A61K47/24 ,  A61K47/26 ,  A61K47/36 ,  A61K47/42 ,  A61K47/44 ,  A61K47/46 ,  A61P1/14 ,  A23V2002/00

Abstract: Disclosed are nutritional compositions including 2′-fucosyllactose (2′-FL) in combination with lutein and RRR-alpha-tocopherol. The nutritional compositions are useful for improving at least one of gut function, health, and development in an individual. In certain embodiments, the nutritional compositions can improve growth or maturation of the gut, as well as promote a healthy balance of beneficial bacteria in the gastrointestinal tract thereby treating and/or preventing formula intolerance or other gastrointestinal diseases and/or disorders resulting from suboptimal gastrointestinal flora population/balance.

公开(公告)号：US20240173292A1

公开(公告)日：2024-05-30

申请号：US18542376

申请日：2023-12-15

Applicant: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA

Inventor： Michael D. L. Johnson ,  Joseph W. Alvin ,  Angela Rivera ,  Wei Wang

IPC: A61K31/397 ,  A61K9/00 ,  A61K31/131 ,  A61K31/145 ,  A61K31/426 ,  A61K31/495 ,  A61P31/04 ,  A61P31/10

CPC classification number: A61K31/397 ,  A61K9/0073 ,  A61K31/131 ,  A61K31/145 ,  A61K31/426 ,  A61K31/495 ,  A61P31/04 ,  A61P31/10

Abstract: Copper is broadly toxic to bacteria. The present invention has identified a compound called N,N-dimethyldithiocarbamate (DMDC) and derivatives thereof that combines with copper to prevent the growth of wild type Streptococcus pneumoniae, and even better, kills Streptococcus pneumoniae. Low micromolar levels of DMDC, complexed with biologically relevant amounts of copper, such as those found in the phagolysosome of the macrophage, has a profound effect in killing up to 99.9% of wild type S. pneumoniae in 2 hours. DMDC also works against S. pneumoniae in an animal model of infection, and in vitro against schistosomes and Coccidioides spp. Additionally, the present invention features a method of treating infections caused by the aforementioned pathogenic organisms, as well as others, by administering DMDC to a patient in need thereof.

公开(公告)号：US20240166618A1

公开(公告)日：2024-05-23

申请号：US18281127

申请日：2022-03-14

Applicant: GILGAMESH PHARMACEUTICALS, INC.

Inventor： Andrew Carry KRUEGEL

IPC: C07D317/58 ,  A61K31/138 ,  A61K31/145 ,  A61K31/277 ,  A61K31/36 ,  A61P25/22 ,  A61P25/24 ,  C07C217/60 ,  C07C255/59 ,  C07C323/32

CPC classification number: C07D317/58 ,  A61K31/138 ,  A61K31/145 ,  A61K31/277 ,  A61K31/36 ,  A61P25/22 ,  A61P25/24 ,  C07C217/60 ,  C07C255/59 ,  C07C323/32

Abstract: The present disclosure provides phenalkylamine compounds and their use in treating medical disorders, such as psychiatric diseases and disorders. Pharmaceutical compositions and methods of making various phenalkylamine compounds are provided.

公开(公告)号：US11986479B2

公开(公告)日：2024-05-21

申请号：US18110238

申请日：2023-02-15

Applicant: PharSoln, Inc.

Inventor： David M. Naeger

IPC: A61K31/52 ,  A61K31/145 ,  A61K31/573 ,  A61P31/14

CPC classification number: A61K31/52 ,  A61K31/145 ,  A61K31/573 ,  A61P31/14

Abstract: Treatments for human subjects exposed to, potentially exposed to, infected by, or potentially infected by a coronavirus, such as SARS-CoV-2, its variants and sub variants are described, which are based on an administration of combination drug products having two or three active ingredients formulated with one or more pharmaceutically acceptable carriers. These patients (children, adults and the elderly) suffer from symptoms of COVID-19, and some may continue to suffer from its aftereffects many weeks or months after an infection, like long COVID, including neurological aymptoms such as brain fog and confusion. Physiological ailments may consist of symptoms such as fatigue, shortness of breath, difficulty breathing, joint and muscle aches, and the like. The two-component combination drug product comprises effective amounts of ANTABUSE (disulfiram) and PURINETHOL (mercaptopurine, 6-mercaptopurine, or 6-MP) or its prodrug IMURAN (azathioprine) or hydrates of these compounds. A three-component combination drug product adds, in addition to the foregoing active ingredients, an effective amount of dexamethasone or pharmacologically acceptable salts thereof.

公开(公告)号：US11981953B2

公开(公告)日：2024-05-14

申请号：US16369939

申请日：2019-03-29

Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION

Inventor： Christina Marie Hull ,  Mingwei Huang ,  Sebastien Claude Ortiz

IPC: C12Q1/18 ,  A01N33/10 ,  A01N37/44 ,  A01N41/12 ,  A01N47/40 ,  A61K31/137 ,  A61K31/145 ,  A61K31/155 ,  A61K31/24 ,  A61P31/10 ,  C12Q1/66

CPC classification number: C12Q1/18 ,  A01N33/10 ,  A01N37/44 ,  A01N41/12 ,  A01N47/40 ,  A61K31/137 ,  A61K31/145 ,  A61K31/155 ,  A61K31/24 ,  A61P31/10 ,  C12Q1/66 ,  G01N2333/375

Abstract: A method of testing compounds for activity to inhibit germination of spores. The method includes the steps of providing bacterial, fungal, or plant spores transformed to contain and express a detectable marker, wherein the marker when expressed, is operationally linked to a spore-specific or yeast-specific protein, in a medium and under environmental conditions in which the spores will germinate, and measuring a first signal output generated by the marker prior to the spores initiating germination; contacting the spores of step (a) with a compound whose activity to inhibit germination of spores is to be measured; incubating the spores of step (b) under environmental conditions and for a time wherein spores not treated with the compound will germinate; and determining extent of germination of the spores by measuring a second signal output generated by the marker, wherein a difference between the first signal output and the second signal output is proportional to the extent of germination of the spores. Also described are compositions of matter for inhibiting spore germination in vitro and in vivo.